Form 4: ARVINAS CAO Sells Shares for Tax Obligations

Arvinas Chief Accounting Officer David K. Loomis sold 1,108 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• David K. Loomis, Chief Accounting Officer of Arvinas, Inc. (ARVN), sold 1,108 shares of common stock.
• The transaction occurred on February 23, 2026, at a price of $12.16 per share.
• The sale was non-discretionary and executed automatically by the issuer to cover tax withholding obligations.
• This sale was in connection with the vesting and settlement of one-half of Loomis's restricted stock units (RSUs) granted on February 23, 2024.
• Following the transaction, David K. Loomis beneficially owns 29,692 shares of Arvinas common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was non-discretionary and solely for tax withholding related to RSU vesting, which is a standard compensation practice.

Positives

• The sale was non-discretionary, indicating it was not a voluntary decision by the officer to reduce their stake due to concerns about the company's future.
• The transaction is a routine event related to RSU vesting, which is a common form of executive compensation.

Negatives

• No specific negatives are identified as the sale was for tax purposes and not a discretionary divestment.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• The sale does not represent a discretionary trade.

Industry Context

StockSavvy.ai notes that routine insider sales for tax withholding purposes upon RSU vesting are common across all industries, particularly in high-growth sectors like biotechnology, where equity compensation is a significant component of executive pay. This transaction does not inherently signal a change in management's outlook on the company's prospects.

Comparison to Industry Standards

• This type of non-discretionary sale for tax purposes is a standard practice for executives receiving equity compensation across publicly traded companies.
• For example, similar tax-related sales are frequently observed at biotech peers like Moderna (MRNA) or BioNTech (BNTX) when executive RSUs vest, and are generally not viewed as a bearish signal compared to discretionary sales.

Related Party Transactions

• No related party dealings beyond the executive's compensation-related stock transaction are disclosed.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is routine and non-discretionary, not signaling a change in insider confidence.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a Chief Accounting Officer to cover tax obligations upon RSU vesting. Such transactions are a standard part of executive compensation and do not reflect a change in the officer's investment sentiment or the company's fundamentals. Therefore, it provides no new information that would warrant a change in an existing investment thesis, suggesting a 'hold' recommendation.

Keywords

Arvinas, ARVN, Form 4, insider transaction, stock sale, restricted stock units, RSU vesting, tax withholding, David K Loomis, Chief Accounting Officer